alendronate has been researched along with Carcinoma in 3 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have recently developed biodegradable, biocompatible nanoparticles (NP) made of a conjugate between poly (D,L-lactide-co-glycolic) acid and alendronate, suitable for systemic administration, and directly targeting the site of tumor-induced osteolysis." | 3.76 | Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. ( Angelucci, A; Avnet, S; Baldini, N; Capulli, M; Castelli, F; Cenni, E; Del Fattore, A; Fotia, C; Giunti, A; Granchi, D; Micieli, D; Pignatello, R; Rucci, N; Salerno, M; Teti, A; Zini, N, 2010) |
| " The aim of this study was to evaluate the effect of antibone resorptive agents, in particular alendronate (ALN) on BMD in postmenopausal osteoporotic women with thyroid carcinoma who were receiving long-term thyrotropin (TSH)-suppressive therapy with thyroxine." | 3.75 | Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. ( Assante, R; Fonderico, F; Lupoli, G; Lupoli, GA; Marciello, F; Martinelli, A; Panico, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parente-Pereira, AC | 1 |
| Shmeeda, H | 1 |
| Whilding, LM | 1 |
| Zambirinis, CP | 1 |
| Foster, J | 1 |
| van der Stegen, SJ | 1 |
| Beatson, R | 1 |
| Zabinski, T | 1 |
| Brewig, N | 1 |
| Sosabowski, JK | 1 |
| Mather, S | 1 |
| Ghaem-Maghami, S | 1 |
| Gabizon, A | 1 |
| Maher, J | 1 |
| Panico, A | 1 |
| Lupoli, GA | 1 |
| Fonderico, F | 1 |
| Marciello, F | 1 |
| Martinelli, A | 1 |
| Assante, R | 1 |
| Lupoli, G | 1 |
| Salerno, M | 1 |
| Cenni, E | 1 |
| Fotia, C | 1 |
| Avnet, S | 1 |
| Granchi, D | 1 |
| Castelli, F | 1 |
| Micieli, D | 1 |
| Pignatello, R | 1 |
| Capulli, M | 1 |
| Rucci, N | 1 |
| Angelucci, A | 1 |
| Del Fattore, A | 1 |
| Teti, A | 1 |
| Zini, N | 1 |
| Giunti, A | 1 |
| Baldini, N | 1 |
3 other studies available for alendronate and Carcinoma
| Article | Year |
|---|---|
Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
Topics: Alendronate; Animals; Carcinoma; Cell Line, Tumor; Cytotoxicity, Immunologic; Female; Humans; Immuni | 2014 |
Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; | 2009 |
Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases.
Topics: Acid Phosphatase; Alendronate; Animals; Antineoplastic Agents; Biological Transport; Bone Density Co | 2010 |